PharmiWeb.com - Global Pharma News & Resources

Press Releases

Date Title Company
25-Apr-2024 Drug Of Abuse Testing Market Projected at USD 11.8 Billion by 2032 | Market.us Wired Release
25-Apr-2024 Diabetes Devices Market Expands: Forecasted Worth USD 68.2 Billion by 2032 | Market.us Wired Release
25-Apr-2024 Hemogenyx Pharmaceuticals PLC Announces Final Results AccessWire
25-Apr-2024 Marinomed Biotech AG enters Solv4U R&D collaboration with Brazilian pharmaceutical company Aché Laboratórios Marinomed Biotech AG
25-Apr-2024 Drägerwerk AG & Co. KGaA: Dräger with solid business performance in the first quarter of 2024 Drägerwerk AG & Co. KGaA
25-Apr-2024 Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance Formycon AG
25-Apr-2024 Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024 Heidelberg Pharma AG
25-Apr-2024 Alfa Chemistry Intensifies Efforts on Transfer, Manufacturing and Modification of Graphene-Based Silicon-Carbon Composites Alfa Chemistry
25-Apr-2024 Three Featured Products Upgraded at Alfa Chemistry: Protection Reagents, Environmental Goods Standards, Porphyrins and Phthalocyanines Alfa Chemistry
24-Apr-2024 Tiger Aesthetics Medical, LLC Acquires Assets of Sientra, Inc. AccessWire
24-Apr-2024 Biophytis Announces Transfer of ADSs to OTC Market AccessWire
24-Apr-2024 Biophytis Announces Transfer of ADSs to OTC Market Biophytis
24-Apr-2024 Assured Imaging Expands Into Virginia Through Pivotal Partnership, Advancing Its Commitment to Saving Lives Through Innovation in Underserved Areas AccessWire
24-Apr-2024 NanoVibronix to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 AccessWire
24-Apr-2024 InnoScot Health backs World IP Day aim of ‘building common future’ through innovation InnoScot Health
24-Apr-2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting AccessWire
24-Apr-2024 MorphoSys To Present New Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2024 ASCO Annual Meeting MorphoSys AG
24-Apr-2024 ChargePoint to expand product range by investing in a dedicated multi-million-pound single-use manufacturing facility ChargePoint Technology
24-Apr-2024 Kynos Therapeutics announces positive top line results from the first-in-human Phase I study of its KMO inhibitor, KNS366, demonstrating safety, tolerability and target engagement Kynos Therapeutics
24-Apr-2024 BioInvent to Present Clinical Data from its Two Leading Assets at ASCO 2024 AccessWire